[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338847-105":59,"doc-detail-338847-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","impact-of-chronic-obstructive-pulmonary-disease-on-the-efficacy-and-safety-of-neoadjuvant-immune-checkpoint-inhibitors-combined-with-chemotherapy-for-resectable-non-small-cell-lung-cancer-a-retrospective-cohort-study","Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer - a retrospective cohort study","","Retrospective cohort evidence evaluates whether chronic obstructive pulmonary disease (COPD) alters treatment outcomes in resectable non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy. The study compares 30 patients with COPD to 44 without COPD, focusing on pathological complete response and survival measures. Results show COPD is associated with a higher PCR rate and a statistically significant effect on progression-free survival and hazard estimates, with an overall acceptable safety profile.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-chronic-obstructive-pulmonary-disease-on-the-efficacy-and-safety-of-neoadjuvant-immune-checkpoint-inhibitors-combined-with-chemotherapy-for-resectable-non-small-cell-lung-cancer-a-retrospective-cohort-study/338847/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-chronic-obstructive-pulmonary-disease-on-the-efficacy-and-safety-of-neoadjuvant-immune-checkpoint-inhibitors-combined-with-chemotherapy-for-resectable-non-small-cell-lung-cancer-a-retrospective-cohort-study/338847.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How was the study conducted and what patient cohort was analyzed?","Question",{"text":113,"@type":114},"A retrospective observational clinical study included 105 consecutive resectable NSCLC patients receiving neoadjuvant ICIs combined with chemotherapy between April 2020 and April 2023 at Tianjin Chest Hospital.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What impact did COPD have on pathological outcomes?",{"text":118,"@type":114},"The COPD group showed a higher pathological complete response (43.3% vs 20.5%, P=0.042). Multivariate analysis indicated COPD presence was significantly associated with PCR.",{"name":120,"@type":111,"acceptedAnswer":121},"Did COPD affect progression-free survival and safety?",{"text":122,"@type":114},"Progression-free survival was not reached in the COPD group, while the non-COPD group had 17 months (95%CI: 12.1–21.9) with statistical significance (χ2=6.247, P=0.012). Adverse events grade 3–4 were reported for both groups, with conclusions stating an acceptable safety profile.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338847,1790149340,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Dong et al. BMC Cancer (2024) 24:153 [https://doi.org/10.1186/s12885-024-11902-w](https://doi.org/10.1186/s12885-024-11902-w)  \nBMC Cancer  \n RESEARCH Open Access  \nImpact of chronic obstructive pulmonary  \ndisease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study  \nWeigang Dong1, Yan Yin1, Shengnan Yang1, Bin Liu1, Xi Chen1, Lina Wang1, Yue Su1, Yan Jiang1, Dongsheng Shi1, Daqiang Sun2* and Jianwen Qin1*  \nAbstract  \nBackground Neoadjuvant immune checkpoint inhibitors(ICIs) combined with chemotherapy can improve nonsmall cell lung cancer(NSCLC) patients’ pathological responses and show promising improvements in survival. Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disease, and its associated abnormal inflammatory response affects not only the immunotherapy efficacy but also immune-related adverse events. It remains unclear whether NSCLC patients with COPD can benefit from neoadjuvant ICIs combined with chemotherapy.  \nMethods A retrospective observational clinical study was conducted on 105 consecutive NSCLC patients receiving neoadjuvant ICIs combined with chemotherapy at the Department of Thoracic Surgery of Tianjin Chest Hospital between April 2020 and April 2023.  \nResults A total of 74 NSCLC patients were included in the study, including 30 patients with COPD and 44 patients without COPD. The percentage of patients with a pathological complete response (PCR) was higher in the COPD group than in the non-COPD group (43 . 3% vs. 20. 5%, P = 0 . 042) . Multivariate logistic regression analysis of factors associated with PCR showed that the adjusted odds ratio (OR) was statistically significant for presence of COPD  \n(OR = 3 . 020, 95%CI: 1.042–8. 757; P = 0 . 042) . Major pathological response (66 . 7% vs. 50%, P = 0 . 155), R0 resection rate (96 . 7% vs.93. 2%, P = 0 . 642), N2 lymph node downstaging(92 . 3% vs. 66. 7%, P = 0 . 182) and objective response rate (70% vs. 63. 6%, P = 0 . 57) were not significantly different between the groups. Progression-free survival(PFS) was not reached in the COPD group and 17 months (95%CI: 12.1–21. 9) in the non-COPD group, with statistically significance  \n(χ2 = 6 . 247, P = 0 . 012) . Multivariate Cox’s regression analysis showed that the adjusted hazard ratio (HRadj) was statistically significant for presence of COPD (HRadj = 0 . 321, 95%CI: 0 .111–0. 930; P = 0 . 036) . The grade 3 and grade 4 adverse  \n*Correspondence:  \nDaqiang Sun [sdqmd@tju.edu.cn](sdqmd@tju.edu.cn)[ ](sdqmd@tju.edu.cn)Jianwen Qin [qinjianwen2005@aliyun.com](qinjianwen2005@aliyun.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero","cbCaihxQD4oasYfi","https://ap.wps.com/l/cbCaihxQD4oasYfi","pdf",1680441,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Disease context and rationale","[{\"question\":\"How was the study conducted and what patient cohort was analyzed?\",\"answer\":\"A retrospective observational clinical study included 105 consecutive resectable NSCLC patients receiving neoadjuvant ICIs combined with chemotherapy between April 2020 and April 2023 at Tianjin Chest Hospital.\"},{\"question\":\"What impact did COPD have on pathological outcomes?\",\"answer\":\"The COPD group showed a higher pathological complete response (43.3% vs 20.5%, P=0.042). Multivariate analysis indicated COPD presence was significantly associated with PCR.\"},{\"question\":\"Did COPD affect progression-free survival and safety?\",\"answer\":\"Progression-free survival was not reached in the COPD group, while the non-COPD group had 17 months (95%CI: 12.1–21.9) with statistical significance (χ2=6.247, P=0.012). Adverse events grade 3–4 were reported for both groups, with conclusions stating an acceptable safety profile.\"}]","Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer - a retrospective cohort study | PDF",1790026131,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b14c64dbc0417b3246305aab9c0977df.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0da5279b6657337aab4890ebfb3c68ad.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1569b164e449735bc037cc341070d1f2.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1939ad5ce790c51893c1597a2219b871.webp",980,1301]